Why the study?
Immune checkpoint inhibitors have improved lung cancer treatment but carry an increased risk of cardiotoxicity, prompting investigation into whether statins can mitigate these cardiovascular risks.
Does statin use reduce major adverse cardiovascular events in lung cancer patients receiving immune checkpoint inhibitors?
Does statin use reduce major adverse cardiovascular events in lung cancer patients receiving immune checkpoint inhibitors?
In lung cancer patients receiving immune checkpoint inhibitors, statin use is associated with a significantly reduced risk of major adverse cardiovascular events and all-cause mortality.
Answers are grounded in this paper and cite their sources.
Statin use may lower MACE risk in lung cancer patients on ICIs; leaves open need for randomized confirmation before practice change.
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with an increased risk of cardiotoxicity. We investigated whether statins could mitigate ICI-associated cardiovascular risks in lung cancer patients. METHODS: We performed a retrospective, propensity score-matched cohort study utilizing the TriNetX database. We identified lung cancer patients receiving ICIs between April 2013 and June 2023. We created two cohorts: statin users and non-users. The primary efficacy outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction, ischemic stroke, and heart failure. The secondary efficacy outcomes were myocarditis and cardiac arrest. Safety outcomes were all-cause mortality and serious immune-related adverse events (irAEs). RESULTS: A total of 16,650 lung cancer patients undergoing ICIs were identified, consisting of 6,812 statin users and 9,838 non-users. After propensity score matching, 4,379 patients were well-matched in baseline characteristics. Over a follow-up period of 12 months, statin use was associated with a lower risk of MACE (HR: 0.87, 95% CI: 0.78-0.98), primarily driven by reductions in myocardial infarction (HR: 0.75, 95% CI: 0.58-0.97) and heart failure (HR: 0.85, 95% CI: 0.74-0.98). For safety outcomes, statin use was associated with a reduction in all-cause mortality (HR: 0.83, 95% CI: 0.77-0.90) and did not result in an increased risk of serious irAEs. CONCLUSION: The use of statins in lung cancer patients with cardiovascular risk factors and without previous cardiovascular events undergoing immunotherapy was associated with a reduction in MACE and all-cause mortality without an increased risk of serious adverse events.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: